{"id":"NCT00123487","sponsor":"Bristol-Myers Squibb","briefTitle":"Advanced Chronic Myelogenous Leukemia (CML) - Follow On: Study of BMS-354825 in Subjects With CML","officialTitle":"A Randomized Two-Arm, Multicenter, Open-Label Phase III Study of BMS-354825 Administered Orally at a Dose of 70 mg Twice Daily or 140 mg Once Daily in Subjects With Chronic Myeloid Leukemia in Accelerated Phase or in Myeloid or Lymphoid Blast Phase or With Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Who Are Resistant or Intolerant to Imatinib Mesylate (Gleevec)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-06","primaryCompletion":"2006-11","completion":"2013-06","firstPosted":"2005-07-25","resultsPosted":"2014-10-22","lastUpdate":"2014-11-03"},"enrollment":638,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Myeloid Leukemia, Chronic, Accelerated Phase","Leukemia, Lymphoblastic, Acute, Philadelphia-Positive"],"interventions":[{"type":"DRUG","name":"dasatinib","otherNames":["Sprycel","BMS-354825"]},{"type":"DRUG","name":"dasatinib","otherNames":["Sprycel","BMS-354825"]}],"arms":[{"label":"dasatinib Twice a Day (BID)","type":"EXPERIMENTAL"},{"label":"dasatinib Once a Day (QD)","type":"EXPERIMENTAL"}],"summary":"This is a phase III study of BMS-354825 in subjects with chronic myelogenous leukemia in accelerated phase, or in myeloid or lymphoid blast phase or with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia who are resistant or intolerant to imatinib mesylate (Gleevec).","primaryOutcome":{"measure":"Percent of Participants With Major Hematologic Response (MaHR) With 6 Months of Follow-up From Date of Last Enrollment - Randomized Population","timeFrame":"Randomization up to 6 months","effectByArm":[{"arm":"Dasatinib 140 mg QD","deltaMin":48,"sd":null},{"arm":"Dasatinib 70 mg BID","deltaMin":47.9,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":11},"locations":{"siteCount":119,"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","Czechia","Denmark","Finland","France","Germany","Greece","Hungary","Ireland","Israel","Italy","Netherlands","Norway","Peru","Philippines","Poland","Russia","Singapore","South Africa","South Korea","Spain","Sweden","Switzerland","Taiwan","Thailand","United Kingdom"]},"refs":{"pmids":["16960978","20131302","19369231"],"seeAlso":["http://www.bms.com/studyconnect/Pages/home.aspx","http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx"]},"adverseEventsSummary":{"seriousAny":{"events":228,"n":304},"commonTop":["Diarrhoea","Headache","Pyrexia","Nausea","Pleural effusion"]}}